|Over a week ago|
Apyx Medical announces FDA 510k submission for use of renuvion » 07:3406/0106/01/21
Apyx Medical announced it…
Apyx Medical announced it has submitted a 510k premarket notification to the Food and Drug Administration, which is intended to obtain a specific clinical indication for the use of Renuvion in dermal resurfacing procedures. "Following the recent completion of our U.S. IDE clinical study evaluating the use of our Renuvion technology in dermal resurfacing procedures, we were pleased to submit our 510k premarket notification for this procedure category on May 28th," said Charlie Goodwin, President and CEO. "This submission is an important milestone that underscores our continued progress in pursuing specific clinical indications to market and sell Renuvion for target procedures in the cosmetic surgery market. I would like to thank our clinical and regulatory teams for their exceptional efforts which has made our recent progress possible, and look forward to the FDA's review of our submission."
|Over a month ago|
Piper Sandler remains buyer of Apyx Medical after 'solid' Q1 » 10:4405/1205/12/21
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien reiterates an Overweight rating on Apyx Medical with a $12 price target citing this morning's "solid beat and raise" quarter. While generator sales are still seeing some lingering impacts from the pandemic, the business grew over 80% year-over-year, with global hand piece sales also strong, growing over 100%, O'Brien tells investors in a research note. The analyst thinks Apyx is set up well for "continued acceleration over the coming years" and he views the current valuation as "reasonable." O'Brien sees a "lot to like with this name" and remains a buyer of the stock.
Apyx Medical sees FY21 revenue in the range of $37.6M-39.7M, consensus $37.82M 07:1405/1205/12/21
Apyx Medical reports Q1 EPS (14c) consensus (14c) » 07:1105/1205/12/21
Reports Q1 revenue $8.6M,…
Reports Q1 revenue $8.6M, consensus $7.84M. "I would like to commend our team on their exceptional efforts during the quarter, which enabled us to achieve first quarter revenue results that exceeded our expectations, driven by strong global sales of our Advanced Energy products," said Charlie Goodwin, President and Chief Executive Officer. "In spite of the continued impacts of the COVID-19 pandemic, we continued to see healthy utilization of our Helium Plasma Technology in the U.S. and key international markets, resulting in total handpiece growth in excess of 100% year-over-year. We were also excited to see global generator sales increase by more than 80% year-over-year, which was driven by strong demand in both the U.S. and our existing international markets. Importantly, we complemented our strong global sales performance in the first quarter with notable margin improvements, due in part to our efforts to reduce the per unit manufacturing costs of our Advanced Energy handpieces and managing our discretionary spending appropriately given the current operating environment."
Apyx Medical set up well for continued growth, says Piper Sandler » 12:2303/3103/31/21
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien reiterates an Overweight rating on Apyx Medical with a $12 price target following the company's better than expected Q4 results. While domestic generator sales continue to be pressured by the pandemic, international stood out, growing 88% year-over-year, O'Brien tells investors in a research note. The analyst thinks Apyx is set up well for continued growth acceleration of the business over the coming years. "Add in a reasonable valuation, and we think there is a lot to like here," he writes.
Apyx Medical sees FY21 revenue of $36.7M-$38.7M, consensus $39.15M » 07:0803/3103/31/21
Adjusted EBITDA loss in…
Adjusted EBITDA loss in the range of $14.6 M $12M compared to adjusted EBITDA loss of $14.5M for the year ended December 31..
Apyx Medical reports Q4 EPS (4c), consensus (11c) » 07:0403/3103/31/21
Reports Q4 revenue…
Reports Q4 revenue $11.5M, consensus $9.62M. Our team brought 2020 to a strong finish by achieving 44% year-over-year revenue growth in the fourth quarter, despite the continued impacts related to the COVID-19 pandemic," said Charlie Goodwin, President and Chief Executive Officer. "In the fourth quarter, we were pleased to see strong, utilization-based demand in the U.S., with handpiece sales increasing 80%, coupled with 75% year-over-year growth in handpiece sales to our international customers. While demand for our generators in the U.S. continued to be affected by the softer capital equipment purchasing environment due to COVID-19, international generator sales increased 88% year-over-year, driven by demand from several of the new countries that we entered during 2020. In addition to our strong sales performance, we also reported solid margin improvements driven by our efforts to reduce the per unit manufacturing costs of our Advanced Energy handpieces, as well as our focus on reducing discretionary spending in response to the challenging operating environment. Lastly, we delivered important progress with respect to our two U.S. IDE clinical studies, which are designed support our pursuit of new clinical indications for target cosmetic surgery procedures."
|Over a quarter ago|
Apyx Medical price target raised to $12 from $8 at Piper Sandler » 05:0701/2901/29/21
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien raised the firm's price target on Apyx Medical to $12 from $8 and keeps an Overweight rating on the shares. The analyst adjusted targets in the medical technology and devices space.
Fly Intel: After-Hours Movers » 18:2301/1301/13/21
PFSW, ORGO, APYX, JWN, HWCC
Check out this evening's…
Apyx Medical sees FY20 revenue $27.1M-$27.5M, consensus $24.35M » 16:1701/1301/13/21
The company sees FY 20 …
The company sees FY 20 revenue in a range of approximately $27.1 to $27.5M, down approximately 3% to 4% year-over-year.;Advanced Energy revenue in a range of approximately $21.9 to $22.2M, down approximately 2% to 4% year-over-year. and OEM revenue in a range of approximately $5.25 to $5.35M down approximately 4% to 5% year-over-year.